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ABSTRACT
ADHERENCE TO THE AMERICAN COLLEGE OF CARDIOLOGYI AMERICAN
HEART ASSOCIATION GUIDELINES FOR PHARMACOTHERAPY IN NEW
YORK HEART ASSOCIATION CLASS II-IV HEART FAILURE PATIENTS AND
ASSOCIATED RE-HOSPITALIZATION RATES
Matthew T. Mefford
April 24, 2013
This thesis will assess differences in the rates of rehospitalization among New
York Heart Association class II, III, and IV heart failure patients, focusing on levels of
adherence to the American College of CardiologylAme ric an Heart Association guidelines
for heart failure patient pharmacotherapy. Hospitalization data on 128 HF patients will be
analyzed looking at 14 day, 30 day, and 6 month time points, assessing key aspects of
treatment and patient characteristics as potential risk factors in predicting
rehospitalization trends. EfIectiveness of ACCIAHA adherence to pharmacotherapy upon
primary hospital discharge will be itemized in an intention to treat analysis, with
guidelines determined by compliance between NYHA classification and ACCIAHA
recommendations. Confounding interactions by demographic characteristics including
race, sex, and age will be included. This study will gauge the effectiveness of current HF
patient care criteria as well as point out potential confounding effects associated with
prescribed care previously unaccounted for in the current literature.
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EPIDEMIOLOGY OF HEART FAILURE:
Heart failure rates, mortality, prevalence, and incidence have been classified by
several different research studies, each with variances in the populations studied and data
collection methods. For example, the Framingham study - which began in 1948 - had a
list of symptoms, physical findings, and physiological measurements used to classifY
congestive heart failure; classification as a case required multiple criteria be met, with no
other medical explanation than heart failure for the presence of "minor" criteria. 17 In
contrast, the development of ACCFIAHA guidelines re-defined HF as a clinical
syndrome characterized by symptoms in the medical history of an individual as well as
signs in a physical examination. With no single diagnostic test for presence of HF, most
diagnoses are subjective and based on qualitative judgment. Interpretation of
epidemiological data of HF is compromised by these variances. Because there is not a
universal classification for heart failure, this limitation should be borne in mind when
considering the following data presented.
The National Health and Nutrition Examination Survey (NHANES) is a program
of studies designed to assess the health and nutritional status of adults and children in the
US and is a combination of both physical examinations of interviews. 6 Results of the
NHANES 2005-2008 estimated that 5.7 million Americans over the age of 20 years have
HF.

26 Projections

on crude prevalence from 2010 show that approximately 6.6 million

Americans (2.8% of the popUlation) had HF, with the trend increasing each year. It's
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estimated that by 2030, with trends continuing upward, an additional 3 million people
will have HF, a 25% increase in prevalence from 2010.

27

Annual rates per 1000

population of new HF events for white men are as much as 15.2 for those 65 to 74 years,
31.7 for those 75 to 84, and 65.2 for those greater than 85 years; for white women in the
same age groups, rates are 8.2, 19.8, and 45.6. For black men, rates are 16.9,25.5, and
50.6, and for black women, rates are 14.2, 25.5, and 44.0. (CHS, NHLBI)
The Multi-Ethnic Study of Atherosclerosis (MESA) was a medical research study
on cardiovascular disease risk factors that involved more than 6,000 men and women
from six communities in the US and was funded by the NHLBI and NIH. Data from
MESA ranked the risk of developing HF by all ethnic groups in the following order:
African American, Hispanic, white, and Chinese American (4.6,3.5,2.4, and 1.0 per
1000 person-years, respectively).27 These differences in risk can be directly correlated
with prevalence of hypertension and other comorbid conditions, as well as socioeconomic
status (SES). African Americans also had the highest proportion of incident HF not
proceeded by clinical myocardial infarction (MI)27 In the ARIC study, age adjusted
incidence of HF per 1000 person-years was 9.1 for black men (BM), 8.1 for black
females (BF), 6.0 for white men (WM), and 3.4 for white females (WF). The 30-day, 1
year, and 5 year case fatality rates after rehospitalization for HF were 42.3% in BM, 22%
in BF, and 10.4% in WM.19 Similarly, the CARDIA study, looking at CVD differences in
young black and white adults, concluded that HF before the age of 50 years was more
common among black individuals. Hypertension, obesity, and systolic dysfunction were
all considered important risk factors in the development of disease and targets for
. 27
preventIOn.
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Risk factor epidemiology for HF patients shows a distinct group of lifestyle
conditions that critically affect the severity of disease onset and progression. The
Framingham study listed lifestyle-related factors increasing risk of HF including
cholesterol concentration, smoking status, blood pressure, and diabetes; presence of left
ventricular hypertrophy (LV H) as a consequence of hypertension - resulting in an
enlargement of the left ventricle - as determined by electrocardiography (ECG) is also
considered a significant risk factor. 17 Older males and females had a higher relative risk
for the development ofHF with the presence of hypertension, diabetes, and LVH: 1.9,
2.0, and 4.9, respectively, in males, and 1.9,3.6, and 5.4 in females. Men aged 35-64 also
had a significantly increased risk of HF development if they were smokers (RR=1.5).17
Among 20,900 male physicians in the Physicians Health Study, the lifetime risk ofHF
was higher in men with hypertension; healthy lifestyle factors (normal weight, not
smoking, regular exercise, moderate alcohol intake, etc) were related to lower risk of
HF.27 Among the participants of the Health Aging, Body and Composition (ABC) study,
there was a higher proportion of HF attributable to modifiable risk factors in black
participants over white participants (67.8% vs. 48.9%); in this study, inflammatory
markers were also attributed to HF risk.27
In 2008, overall death rate for HF was 84.6 per 100,000 individuals; the rates
listed by varying race/sex class were listed as 98.9 for WM, 102.7 for BM, 75.9 for WF,
and 78.8 BF. (NCHS, NHLBI) Any-mention mortality with HF was 281, 437 (124,598
males and 156,839 females) with HF as the major underlying cause in 56,830 ofthose
deaths in 2008. Additionally, 1 in 9 deaths had HF listed on the death certificate. 27
Survival after HF diagnosis has improved over time, as shown by data in the Framingham
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Heart Study (FHS) and the Olmsted County study. However, death rate remains highapproximately 50% of people diagnosed with HF will die within an average of 5 years. 27
A unique aspect of HF mortality is the proportion of deaths that are sudden. The FHS
predicted that between 40-50% of deaths in the presence of HF were sudden, defined as
occurring within one hour in a previously stable patient. 17 When looking at 30 year
follow up in the Framingham population, the presence of previous HF increased the risk
of sudden death as much as sevenfold when CHD was absent and nine-fold in the
presence of CHD.17
Data from Kaiser Permanente suggest that survival after the onset of HF has
improved in elderly populations, although mortality rates are still high.2 For women ages
65-74, 15 year mortality rates were approximately 60%; the corresponding rate of men in
the same age group was even higher. 17 This improvement seen over time can be
attributed to advancements in surgical and treatment approaches in HF management 17 .
The one area in which rates do not improve for heart failure patients lies in the
hospitalization and rehospitalization data. From 1999 to 2009, hospital discharges for HF
were virtually unchanged, with first-listed discharges of975,000 and 1,094,000
respectively. (NHDS 2009, NCHS, NHLBI)Despite the insignificant change in discharge
rates, rate of hospitalization for HF has increased more than threefold over the past three
decades, with the increasing pattern largely being attributed to elderly populations. One
age group where a positive trend is also witnessed is in the 45-64 year age group.17 With
this said, the overall case-fatality rate has substantially declined by more than 50%
through the 1980's and 1990's.17

4

The amount of heart failure treatment paints an even larger picture of the overall
burden of the disease, with HF imposing a large economic burden on the health care
system. In developed countries, the cost of HF care constitutes approximately 1% to 2%
of overall health care spending. 9 In 2009, the estimated direct and indirect cost of treating
HF patients in the United States was more than $37 billion, this being the largest
consumer of Medicare spending above any other diagnosis. 4 Alarmingly, this figure may
increase in following years due to the aging population and increased survival after
primary hospitalization. Elderly patients, often covered by Medicare, are rehospitalized
more frequently than younger HF patients - 25% being rehospitalized in the first 30 days;
Medicare, however, does not reimburse hospitals for this time period shifting the cost
burden to the healthcare facility.
In a study looking at the lifetime medical costs ofHF patients in Olmsted County,
Minnesota, 1054 patients were randomly sampled and assessed for total accrued debts9 .
Total costs for the cohort during the study period (1987 to 2006) were estimated at $100,
967,086 in 2006, combining both inpatient and outpatient costs. 9 The majority of costs
were due to hospitalizations (77%) with an average cost of $73,762 per person. The
highest proportion of inpatient costs were rooming, procedures, and evaluation and
management. Total outpatient costs accounted for over $22 million, with an average cost
of$22,032 per person. 9 The highest proportion of outpatient cost was due to evaluation
and management and procedures. Among evaluation and management, office visits
comprised the largest amount of cost. Dialysis, if needed, was the largest proportion of
procedural cost. Lifetime costs were estimated for all patients at approximately $109,541
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per person, with comorbid conditions such as diabetes increasing estimated costs over
30%.9
Although overall trends are decreasing for incidence of HF, the cost burden
associated with the management of heart disease is highly significant. In 2009, the US
spent $2.6 trillion on health care, representing more than 17.6% of our gross domestic
product. 9 Although annual costs of caring for the populations affected by HF in the US
are estimated as being high, little is known about the cumulative costs of caring for HF
patients after diagnosis. Some estimates suggest that over 50% of the total costs were
accumulated within the last 6 months of the individual's life. 9 Identifying patient factors
associated with higher costs may be helpful in targeting those patients for cost-saving
interventions. Additionally, standardizing treatment practices among physicians and
medical institutions may improve patient outcomes and reduce the total cost associated
with this disease.
PATHOPHYSIOLOGY/ETIOLOGY OF HEART FAILURE:
Heart failure (HF) is a chronic, progressive condition in which the heart muscle is
unable to pump enough blood to meet the body's needs for oxygen and nutrients. I In
order to compensate for this reduction in blood flow and increase in demand from
surrounding body tissue, the heart will typically undergo one of the following:
enlargement, increase in muscle mass, or increased pumping action. The body in addition
will compensate in other ways: blood vessels can narrow to maintain blood pressure
(making up for the reduction in pumping action/power), or divert blood from less
important tissues and organs to maintain flow to the vital organs (i.e. the heart and
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brain).l While these temporary solutions can delay the outcome of total heart failure,
conditions will worsen until these substitute process no longer work, or some type of
medical intervention occurs. Once an individual's body compensation cannot keep up
with the energy demands it he/she will experience fatigue, breathing problems, or any
myriad of life threatening symptoms -- the most severe being death.
HF primarily reflects the impairment of the pumping function of the heart's left
ventricle, although other etiologies exist. 17 The result of this impairment is a reduction in
blood flow from the left ventricle to the aorta, which in tum reduces peripheral arterial
blood flow. In LV failure, the left side of the heart must exert a larger amount of energy
to pump a normal amount of blood. This increase in exertion often leads to a hardening of
the left ventricular wall ("stiffness") or enlargement of the ventricle (left-ventricular
hypertrophy). Additionally, failure to eject blood from the left ventricle leads to an
increased back pressure in the pulmonary circulation, accompanying and exacerbating
respiratory dysfunction. Heart failure can occur on either the left or right side, with each
classification having distinguishing impairments. Mechanisms of left heart failure include
"systolic" and "diastolic" dysfunction. Systolic dysfunction describes a heart with
diminished ejection fraction, where the left ventricle expels a reduced amount of blood at
each contraction of the myocardium; diastolic dysfunction describes an incomplete
relaxation of the left ventricle (typically due to stiffness of the ventricular wall), resulting
in a reduced volume of blood entering the chamber during each relaxation. 17
The heart moves deoxygenated blood that returns to the heart through the veins
through the right atrium into the right ventricle. The ventricle then pumps blood back out
of the heart into the lungs to be replenished with oxygen. Right-sided heart failure occurs
7

due to an impainnent of right-ventricular (RV) function, and occurs as a result ofleftsided, LV failure. 1 Increased fluid pressure in the lungs, which often times occurs due to
left-sided failure, damages the right ventricular tissue. When the right side loses power,
blood backs up in the body's veins, typically resulting in peripheral edema in the legs and
ankles; right failure also occurs in conjunction with obesity or sleep-disordered
· 17
breath mg.
A myriad of conditions can damage or weaken the heart and cause heart failure.
The most common fonn of heart disease and the a leading cause of HF is coronary artery
disease (CAD)?O CAD is one of several tenns referring to atherosclerosis, or narrowing
of the arteries that supply blood to the heart due to a build-up of fatty deposits. This
slowing of blood flow through the body leaves areas of the myocardium weak and
oxygen deprived. In most cases, however, the reduction in blood flow is not enough to
fully impair the heart muscle, but sufficiently weaken cardiac output; if plaque build-up
occludes the arteries to the point in which myocardial cells are deprived of blood flow
(ischemia), weakening or death of cell tissue occurs. When these plaques rupture, blood
clots block blood flow to an area of the heart muscle, weakening the heart's pumping
ab1'l'lty. 20

Other contributing factors to heart failure include hypertension, heart valve
dysfunction, cardiomyopathy, myocarditis, congenital heart defects, heart arrhythmias,
and other diseases. Hypertension, one of the most common chronic conditions related to
vascular health (affecting more than 70 million Americans), is a critical measure of
circulatory function. 17 It reflects a balance between the blood volume ejected from the
left ventricle of the heart during each contraction and the arterial resistance to blood flow.
8

Several physiologic mechanisms operate to simultaneously maintain blood pressure
based on the perfusion needs of surrounding body tissues. Hypertension, however, causes
the heart to work harder than normal to pump blood throughout the body, which leads to
thickening of the myocardium to compensate for the extra work it must perform. Over
time, the cardiac muscle becomes either too stiff or too weak to effectively pump blood?O
Valve damage, typically due to a heart defect, CAD, or infections, forces the heart to
overexert to keep blood flowing in the normal direction. Myocarditis, an inflammation of
the heart muscle (commonly caused by infection) can also lead to left-sided failure.
Congenital heart defects, those present at birth, are a product of improper
development/formation of the chambers or valves of the heart. As a result, the healthy,
developed portions of the heart have to increase work load to pump blood through the
heart, which can in tum lead to heart failure. In addition, abnormal heart rhythms, or
arrhythmias, can cause the heart to beat too quickly. This too creates extra work for the
heart to pump blood correctly. A slow heart beat may prevent the myocardium from
pushing enough blood out to the body; both scenarios cause a weakening of the
myocardium and can lead to HF. Chronic conditions such as diabetes, anemia,
hyperthyroidism, hypothyroidism, emphysema, lupus, or a build-up of iron, protein, or
inflammatory cells can also contribute to heart failure.

20

Finally, acute heart failure can

be brought on by viruses that attack the myocardium, severe infection, allergic reactions,
blood clots in the lungs, and certain medications?O
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CLASSIFICATION AND STAGING OF HEART FAILURE:
The New York Heart Association (NYHA) classification system is one of the
oldest attempts to grade the severity of functional limitation among heart failure patients.
Initially developed in 1928, this classification scheme, although modified since its
inception, has withstood the test oftime and is still widely used by physicians today; its
accuracy, however, is widely debated. The scale is divided into four functional groups
(class I - least severe to class IV - most severe), separated by a series of qualifying
descriptions related to an individual's physical ability. To accurately assess the extent of
functional limitation, the NYHA committee prescribes using a series of exercise tests to
determine the extent to which patients with impaired or limited cardiac function can
perform without discomfort. The determination of physical impairment spans from class I
patients, who exhibit no limitation in physical activity, to class IV patients, who
experience discomfort performing any physical activity. Full descriptions of the four
classes are listed as such:
New York Heart Association (NYHA) Functional Classification for Heart Failure
Patients:
NYHA Class
I (Mild)

II (Mild)

III(Moderate)

IV (Severe)

Symptoms
No limitation of physical activity. Ordinary physical
activity does not cause undue fatigue, palpitation, or
dyspnea.
Slight limitation of physical activity. Comfortable at
rest, but ordinary physical activity results in fatigue,
palpitation, or dyspnea.
Marked limitation of physical activity. Comfortable at
rest, but less than ordinary activity causes fatigue,
palpitation, or dyspnea
Unable to carry out any physical activity without
discomfort. Symptoms of cardiac insufficiency at rest.
If any physical activity is undertaken, discomfort is
increased.
10

Although widely respected, the guidelines to determine these classifications are
subjective, with no set physical examination guidelines or standards; there are an endless
number of physical exertion tests one can perform to come to the same conclusion.
Additionally, there are no set guidelines to distinguish different levels of ability, with
terms like "slight" or "marked" leaving the interpretation of limited physical ability up to
the physician. Common criteria used to determine NYHA class include: self-reported
walking distance, difficulty climbing stairs, ability to walk to local landmarks,
breathlessness interfering with daily activity, and breathlessness when walking around
the house. 26 While some methods (such as walking distance) are more widely used than
others not one distinct assessment has been accepted as superior to others, although the
ACC has distinct parameters for classification; single clinics creating original
classification schemes often protect their intellectual property from being used across
mUltiple institutions. This inconsistency is apparent in the published literature, with 99%
of research papers withholding a reference or description of their methods for assigning
NYHA class in subjects. 26
However subjective the classitication system, the NYHA scheme is simple
enough to provide a measure of the functional capability in heart failure patients and
allow physicians to relay immediate feedback to these individuals. However one decides
its magnitude of importance, it has no basis in the prescription of medication or course of
treatment. Rather it allows a physician to gauge the extent of disease progression without
medical testing. For more extensive criteria on the classification of heart disease, other
organizations have created guidelines that are widely used today. The best example heart
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failure treatment guidelines are those formulated by the American College of Cardiology
and the American Heart Association, who in a joint task force issued the Guidelines for
the Evaluation and Management of Chronic Heart Failure. These guidelines offer a
comprehensive determination scheme involving both determination of disease
progression and level of evidence in suggesting pharmacotherapies.
The ACC/ AHA first published guidelines for the evaluation and management of
HF patients in 1995, and a great deal of progress has been made since its inception both
in the area of pharmacological and non-pharmacological approaches to treatment.
Although the most current update of guidelines occurred in the year 2009, for purposes of
this thesis the guidelines presented in 2001 will be used; this will maintain continuity
with the time frame of the study data, which was collected in 2004-2005. The committee
composed of7 members representing the ACC and AHA, identified 4 stages ofHF,
similar yet distinguishable from the NYHA classification. Stage A classifies patients who
have a high risk for developing HF, but show no structural disorder of the heart; Stage B
refers to a patient with a structural disorder of the heart but who not yet developed
symptoms of HF; Stage C classifies a patient with past or current symptoms of HF
associated with underlying structural heart disease; Stage D denotes patients with endstage disease who require specialized treatment strategies. 14 Only the latter two stages,
according to clinical diagnostic guidelines, qualify as HF. In comparing to the NYHA
guidelines, class I-IV would only classify those individuals in stage CorD of the
AHA/ ACC guidelines. 14
In contrast to the NYHA classification system, the ACC/AHA developed classes
(in addition to stages of disease) that correspond to levels of evidence on treatment
12

protocol, and provide recommendation on the appropriate course of treatment to prescribe
given the progression of heart disease. Class I describes a condition for which there is
evidence and/or general agreement that the procedure or treatment is useful and effective;
Class II describes a condition for which there is conflicting evidence and/or a divergence
of opinion about the usefulness/efficacy of a procedure or treatment; Class IIa describes a
condition in which the evidence or opinion is in favor of the procedure or treatment;
Class lIb describes a condition for which usefulness or efficacy less well established by
evidence or opinion; and Class III describes conditions for which there is evidence and/or
agreement that the procedure or treatment is not useful/effective and in some cases can be
harmful. 14 Each class has levels of evidence indicated by a grading scale of A, B, and C.
Levels of evidence are ranked as A if the data is derived from multiple randomized
clinical trials, B when data were derived from a single randomized trial or
nonrandomized studies, and C when the consensus opinion of experts was the primary
source of recommendation. 14 The table showing the various classes and levels of
evidence is listed below:
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The ACC/ AHA guidelines clearly lay out treatment recommendations based by
stage, class, and level of evidence. Its advantage over the classification system of the
NYHA lies in that it objectively identifies patients in the course of their disease and links
them to treatment appropriate at each stage of their disease; the NYHA system, in
contrast, offers little variation in treatment recommendation as it subjectively classes
subjects based on non-clinical assessment. 14 In addition, the ACC/AHA approach expects
that each patient advances from one stage to the next until progression is slowed or
stopped by treatment. 14 Despite the inconsistencies between the two systems, they both
remain invaluable in the classification and treatment of HF patients, as modeled by
research on the relationship between class and outcome (with NYHA guidelines) and
treatment, class, and outcome (with ACC/AHA guidelines).
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PHARMACOTHERAPY OF HEART FAILURE:
ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS:
Of the myriads of medications prescribed to patients hospitalized with heart
failure, angiotensin-converting enzyme (ACE) inhibitors are arguably the most widely
used in the course of treatment. ACE inhibitors function by relaxing the blood vessels
and are primarily used in the treatment of hypertension. Biologically, the mechanism
involves ACE inhibitors preventing enzymes in the body from producing angiotensin II a hormone that affects the cardiovascular system by narrowing blood vessels and
releasing hormones that raise blood pressure - forcing an increase in cardiac output. 20
Commonly prescribed examples of ACE inhibitors include: benazepril, captopril, and
enalapril. To determine the importance of ACE inhibitors outside of hypertension
therapy, several randomized clinical studies have assessed the role of ACE inhibitors in
patients with acute myocardial infarction (AMI) or HF.
An analysis of three trials using HF patients enrolled within a week of HF
hospitalization and randomly assigned to either treatment or placebo groups modeled the
effect of ACE inhibitors. Of the 12,763 patients in these studies, individuals prescribed
ACE inhibitors had overall lower mortality (OR = 0.74; 95% CI 0.66-0.83) relative to the
placebo group. Rehospitalization rate, reinfarction rate, and composite of all these events
were also 10wer.27 Additionally, these benefits were independent of age, sex, and other
factors that commonly contribute as competing factors in the effects model. Other studies
have focused on specific populations of individuals to model the effects of ACE
inhibitors. Looking at the effects of these medications in older individuals, an average
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reduction in mortality (approximately 10%) was found among ACE inhibitors users
relative to use of other medications such as Digoxin. 13
ANGIOTENSIN RECEPTOR BLOCKER (ARB):
Angiotensin Receptors Blockers (ARBs), also known as angiotensin II receptor
antagonists are commonly prescribed medications in the treatment of hypertension.
Similar in effect to ACE inhibitors, but alternatively prescribed due to ACE-I intolerance,
they have also proven effective in the treatment of heart failure. At the most basic
description, ARBs function by relaxing the blood vessels and lowering blood pressure,
allowing the heart to pump blood with greater ease. From a biological perspective, the
mechanism of angiotensin receptor blockage directly affects the renin-angiotensinaldosterone system (RAAS) by reducing the secretion of vasopressin and reducing the
production and secretion of aldosterone. Commonly prescribed examples of ARBs
include: candesartan, eprosartan, and losartan. Studies evaluating the role of ARBs in HF
treatment, although less abundant than those focusing on ACE inhibitors, provide insight
on their effectiveness relative to other therapies.
In a randomized trial evaluating HF patients receiving ARBs or placebo
throughout the course of study, combined end point mortality was lower among those
receiving ARB (RR = 0.87; CI (0.77-0.97). Treatment with ARB also improved ejection
7

fraction, NYHA class, and reported quality oflife. The ELITE study, evaluating the
effectiveness of ARBs in an elderly population of HF patients, showed a risk reduction of
32% among those using the medication relative to ACE-inhibitor use, primarily due to a
decrease in all-cause mortality; hospitalization rates were less frequent among ARB
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users, as wel1. 24 ARB prescription is a common alternative to ACE-inhibitors due to their
lack of adverse effects in patients. The ELITE-II study, in follow-up to the original study,
aimed to determine if one course oftreatment was superior to the other (ACE-I vs. ARB).
In the population studied (not just the elderly, as in ELITE) while mortality and sudden
death rates remained similar, the discontinuation of treatment in the ARB group due to
adverse effects was significantly lower than in the ACE-I group (9.7 vs. 14.7, p<0.001).23
Overall, the study on efficacy of these two treatments has proven that either medication is
beneficial in the pharmacotherapy of HF patients.
BETA-BLOCKERS:
Beta adrenergic receptor antagonists, commonly known as beta-blockers, are a
class of drugs that block the effects of epinephrine on the beta receptors found in smooth
muscle, airways, arteries, kidneys, and most importantly, the heart; beta-blockers reduce
blood pressure by negating the effect of epinephrine, thereby reducing heart rate. Betablockers have proven effective in reducing overall mortality among HF patients, as well
as improve LV function. 8 In a meta analysis of randomized trials involving patients with
congestive heart failure, there was a greater than 30% reduction in odds of death among
patients assigned a beta-blocker (CI 11-46%), representing an absolute reduction in mean
annual mortality from 9.7-7.5%.8 Carvedilol, the most commonly prescribed betablocker, has been proven to effectively reduce mortality among patients with moderate to
severe HF. In a random trial of HF patients (NYHA class III or IV) mortality was
reduced by 35% among patients prescribed carvedilol, with an almost 25% reduction in
combined mortality.22 Beta-blockers usage among moderate HF patients showed an
average death rate of 8% compared to 12.8% among non-users (OR=0.63, 95%CI 0.5517

0.72); similar reductions were observed for hospital admissions for worsening HF, and
composite outcome of death.
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SPIRONOLACTONE:
Spironolactone is commonly used in combination with other medications (such as
those listed previously) to treat hypertension and HF. Although a relatively old
medication, introduced clinically in 1959, its importance in HF management and
treatment is often understated, as exhibited by a low level of evidence in ACC/AHA
guidelines for severe HF. In the RALE study of severe HF patients, a relative reduction
of 30% was witnessed among those prescribed spironolactone as opposed to placebo
(RR=0.70; 95% CI 0.60-0.82). This significant reduction was attributed to lower risk of
death from progressive heart failure and sudden death from cardiac causes. Additionally,
hospitalization rates were reduced by 35% and patients had a significant improvement in
the symptoms of heart failure as assessed on the basis of their NYHA functional class. 25
Spironolactone added to ACE-inhibitors has been proven beneficial to improve heart
dysfunction, as well. 3 Where the RALE study proved treatment was beneficial in patients
with severe HF, data to support the beneficial effects in all HF patients remains
inconclusive. Some research suggests an increase in adverse outcomes associated with
spironolactone use when the RALE study guidelines for patient evaluation are not met. 5
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DATA AND METHODS:
The data used in this thesis was derived from "Home HF care comparing patientdriven technology models", an AHRQ funded and IRB approved clinical study. This
parallel, randomized, multi-site prospective cohort study assessed the impact of health
information technologies on clinical and financial outcomes for patients with
symptomatic (NYHA class II - IV) heart failure (HF). The information technologies
include remote monitoring (telemonitoring) of vital signs and symptoms, an electronic
health record system, and clinical decision support systems. Two different configurations
of health information technology were used: technology supported case management, a
combination of telemonitoring and telephone nurse case management, and computerbased self management, which combined telemonitoring with an expert clinical decision
support system that assessed vital signs and symptoms for risk of decompensation.
(Goldberg, 2004) Patients were recruited from both urban and rural areas, including
southern Montana, northern Wyoming, Philadelphia, and southern New Jersey; these
geographic regions included Native American, African American, Caucasian, and
Hispanic HF patients.
In total, 134 patients were recruited for the initial study. The index event for each
patient was the date of primary hospitalization for HF. Patients were enrolled within 18
months of their primary hospitalization date and evaluated over the span of one year after
enrollment for subsequent hospitalization dates. Reasons for subsequent hospitalization
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included heart failure, cardiovascular-related causes, and non-CV -related causes
(classified as "all cause"). In this analysis, if patients upon their first rehospitalization
were classified as "all cause" but had a later rehospitalization for CV or HF -related
causes, they were classified in the CV/HF-rehospitalization group with the first
rehospitalization date being used to calculate their time-to-event; this assumes that the
first rehospitalization could be attributed to an underlying cardiovascular deficiency
which would lead to subsequent heart failure. Of additional importance to this analysis
were specific periods of time in which subsequent hospitalization occurred, including: 014 days, 15-30 days, 31-180 days, and greater than 180 days. The rate of rehospitalization
is important to medical institutions treating HF patients, with respect to the bylaws of the
Affordable Care Act (this will be discussed in a later section). Six patients in total were
excluded from the analysis: 2 were excluded for having less than 1 month of follow-up,
and 4 were excluded for having no index event (i.e., were admitted directly to an
emergency room) - this made the final patient count 128.
Demographic variables including age, sex, and race were recorded for all patients;
data on education, marital status, and living situation were incomplete in some patients as
this information was self-reported. In addition, comorbid conditions and treatment
therapies were recorded for each patient. Comorbid conditions - assessed at enrollment included obesity (BMI> 30), hypertension, hyperlipidemia, hypercholesterolemia,
diabetes I and II. Obesity was coded binomially, while the remaining comorbid
conditions were coded as "doesn't have" - 1, "does have" - 2, or "not determined" - 3;
those with a non-determined status were based on incomplete hospital data. Smoking
status was classified in 4 categories: "never smoked" - 1, "used to smoke" - 2, "currently
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smokes" - 3, and "not determined" - 4. Treatment therapies included prescription of
ACE inhibitors, ARBs, Beta-blockers, Spironolactone, as well as the total number of
prescriptions each patient had been prescribed at enrollment; all treatment variables were
categorized binomially as either "prescribed" or "not prescribed" (1 or 0) with the
exception of number of total prescriptions, which was a continuous variable.
The compliance variable gauging ACC/AHA treatment guidelines for each
NYHA class was based on an all-or-none approach (0 for non-compliance and 1 for
compliance), based on the recommendations for clinical practice put forth from the AHA;
partial compliance was not used due to limited information in the original study set with
regard to baseline clinical measures, which would have accurately provided conditional
situations for modified treatment. In cross-relating the two classification systems, Class II
and Class III in the NYHA corresponded with stage C heart failure patients of the AHA
guidelines. Class IV in NYHA classification corresponded with stage D heart failure
patients of the AHA guidelines. Compliance criteria are listed below, and are based on
the 2001 ACC/AHA guidelines for treatment therapy:
NYHA Class II: ACE inhibitor or ARB
NYHA Class III: ACE-lor ARB and Beta-blocker
(Spironolactone prescribed if LVEF <40%)
NYHA Class IV: ACE-lor ARB, Beta-blocker, and Spironolactone

The guidelines used in this analysis, although outdated by additional updates from the
ACC/ AHA, correspond with the time frame in which the study was conducted; from this,
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the assessment of compliance was accurate in the study data. The most recent guidelines
issued in 2012 remain similar in treatment recommendations based on levels of evidence.
RESULTS:
The goal of this research analysis was to compare trends in re-hospitalization and
event rates among patients with a primary hospitalization for HF, looking at various
factors including age, race, sex, NYHA class, and living situation, as well as
comorbidities (ex: hypertension, hypercholesterolemia, hyperlipidemia, diabetes,
obesity). Outside of analyzing treatment guideline adherence, it is important to look at
multiple factors that can affect an individual's health status, especially studying heartrelated illness. In order to obtain an accurate picture of the health of the individuals in
this study population, it is important to assess their health characteristics at various stages
of heart failure. Descriptive statistics of the study population stratified by their NYHA
functional classification is listed in the table 1.
Table 1. Descriptive Statistics for each NYHA class

NYHA Class

II

III

IV

Mean Age
Sex (male) %
Race %
BMI>30 %
Smoker (ever) %
Hypertension %
Hypercholest. %
Hyperlipidemia %
DM%
Lives alone %
CV /HF rehosp. %
ACC/AHA
compliance %

66
54
84 (C), 15(AA)
49
27
75
36
44
36
33
22
76

66
29
69 (C), 22 (AA)
58
44
80
17
41
34
39
44
56

64
36
79 (C), 14 (AA)
64
52
93
14
57
79
36
43
29
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With the exception of mean age, each NYHA class group of patients has distinct
differences. Of note, proportion of females, average 8MI, smoker status, hypertension,
hyperlipidemia, and diabetes mellitus all increase with increase in NYHA class. The
comorbid conditions listed provide evidence of the deteriorating overall health of the
patient, which may contribute to a decline in cardiovascular health; conversely, the
deteriorating condition of the heart may provide a direct influence on any of these several
conditions, most notably hypertension. One notable decline with an increase in NYHA
class is ACC/AHA compliance, with 76% compliance in the NYHA class II group, 56%
in the class III group, and only 29% in the class IV group (which should be receiving the
most careful treatment of all patients).
Overall rehospitalization rate within the study period was 59%, translating to 76
total patients; of these, 44 patients were re-hospitalized with a primary or secondary
diagnosis for HF (secondary diagnosis was defined as any cardiovascular-related
hospitalization). In the evaluation of guideline compliance for treatment therapies, 44.9%
(22/49) of patients were rehospitalized for HF when ACC/AHA guidelines were NOT
met, compared to 27.8% (22/79) among those patients in which guidelines for treatment
were fulfilled. A risk reduction was exhibited among all individuals over the study
period (1 year) when treatment guideline adherence was met. This decreased risk across
the entire study period provides a baseline trend for the benefit of compliance, although
variations exist at different time periods (listed in table 2).
To estimate the effect of time on risk of rehospitalization more precisely, relative
risks were calculated for following time intervals: 0-14days, 15 days-l month (30 days),
31 days to 6 months (180days), and cumulative 30 day; cumulative risk was also
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calculated for the entire study period. Relative risks for age (2:65 years vs. younger than
65 years), race (white vs. non-white), and sex (male vs. female) were calculated for each
time interval, as well as the relative risk for NYHA class (class IV vs. IIIIII) and
ACC/ AHA compliance variables. Each relative risk calculated was controlled for study
arm to account for treatment differences patients may have received, be it from a
cardiologist, general practitioner, or nurse. The results are listed (along with 95% CI) in
Table 2:
Table 2: Relative risk analysis over I year of observations at various time intervals

oto 14 days
9.12
(95%CI 1.10,
75.0.)

15 to 30 days
2.02
(0.50, 8.21)

0-30 days
2.26
(0.96, 5.29)

3 I to 180 days
0.90
(0.57, 1.43)

Overall
0.89
(0.55, 1.45)

Sex (male vs.
female)

1.13
(0.25,
5.0284)

0.87
(0.22,3.43)

0.998
(0.64, 1.54)

1.20
(0.76, 1.88)

0.74
(0.44, 1.26)

Race (white
vs. other)

0.17
(0.04,0.70)

0.58
(0.15,2.27)

0.44
(0.22,0.83)

0.97
(0.57, 1.66)

0.73
(0.19,2.73)

NYHA class
(2&3 vs. 4)

0.11
(0.02,0.53)

0.60
(0.07,5.11)

0.24
(0.09, 0.61)

1.03
(0.48, 2.20)

0.78
(0.38, 1.57)

AHA
Compliance
(1 vs. 0)

0.23
(0.86, 22.82)

1.95
(0.36, 11.11)

0.79
(0.44, 1.44)

0.85
(0.53, 1.32)

0.65
(0.34, 1.02)

Age (>65
years vs.
under 65)

Relative risk of rehospitalization among elderly individuals (over 65 years) was
greatly increased in the first 30 days of enrollment (RR 0-14 days = 9.12, RR 15-30 days

= 2.02), with later time periods reflecting a lower relative risk than the under 65 years
group. This result can commonly be attributed to a survival effect, with worse prognosis
among older individuals with multiple hospitalizations. Men, although exhibiting a higher
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relative risk of rehospitalization within the first two weeks of the study period, had an
overall lower relative risk of rehospitalization (RR 0.74) compared to women in the
study. Additionally, white individuals had a lower overall relative risk of
rehospitalization compared to other ethnicities; in particular, white individuals exhibited
an almost 90% risk reduction relative to other ethnicities in the 0-14 day rehospitalization
period (RR 0.11).
NYHA classes II and III patients relative to class IV patients had a substantially
reduced risk of rehospitalization, especially within the first two weeks of enrollment (RR
0.11; 9S%CI 0.02, 0.S3). The trend can be seen in each time period where risk was
calculated, with the an overall risk reduction of 22% in class II and III patients compared
to the class IV patients. The most important factor, however, was the risk among those in
which treatment guidelines were not met. Among those individuals in which guideline
compliance was met, a 36% decrease in risk was exhibited over the entire study period
compared to those in which treatment guidelines were not met (RR 0.63; 9S%CI 0.34,
1.02; p=0.06). The first two weeks of enrollment in particular proved to substantially
increase the risk of rehospitalization (RR=0.23; 9S%CI 0.04,1.16). It should be noted
that while not all ofthe relative risks calculated reached statistical significance at the
p=O.OS level, these estimates are of clinical importance due to their representation of a
real (randomized) population of individuals with HF.
Because the cohort was monitored from baseline enrollment to 1 year after, the
appropriate determination of the importance of treatment guideline compliance was to
perform a survival analysis on the subjects, looking at those in which guidelines were met
and those in which guidelines were not complied with. To account for interactions among
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multiple covariates, a Cox regression analysis was performed using SPSS (v. 21) to
model the relative survival among individuals suffering a CV -related hospitalization or
HF -related hospitalization looking at variability among NYHA class and ACC!AHA
guideline compliance. Univariate regression models were run for each of the 5 variables
of interest: age (classified in 2 groups: over!under 65 years old), race, sex, NYHA class
(class IV vs. class II and III), and ACC! AHA compliance. From the univariate analysis,
the log-rank test was performed to determine survival differences among the groups in
each variable. From these analyses, NYHA and treatment compliance both exhibited a
strong effect on failure rates. Age did not reach statistical significance (p=O.232) in the
univariate regression analysis, but was added to the multivariate model due to the older
population of individuals used in the study (mean age = 65 years). Race and sex did not
provide a strong indication of any risk differences and were excluded from the final
model.
A baseline Cox Proportional Hazards model was created looking at
rehospitalization for CV or HF-related causes, and was stratified by those individuals in
compliance with ACC!AHA treatment guidelines and those not in compliance; to negate
differences which may be created by differences in the quality of treatment received,
study arm was used as a control variable. Age and NYHA were both kept dichotomous,
with the age cut point at the mean for the study population. The baseline regression
equation is listed below:

logefP = fllAge

+ flz

NYHA Class

+
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fl3AHA Compliance

+

fl4Study Arm

Likelihood ratio testing was used to evaluate the parameters of the suggested survival
model. Interaction terms were tested at various iterations, with no interactions proving a
strong effect in which they would be adequately added to the survival model without
statistical power. Overall, survival analysis with the baseline model was run looking at
the associated hazard rates in the listed variables for different time periods: 0-365 days
(overall), 0-14 days, 15-30 days, 0-30 days, 31-180 days, and 0-180 days; the plots are
listed below, along with their cumulative hazard ratios.
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CONCLUSIONS:
Over the course of the year in which the study was conducted, a decreased hazard
rate (HR: DAD; 9S%CI: 0.20, 0.81; p=O.OI) was observed in patients in which ACC/AHA
treatment guidelines were met. The largest hazard rate decrease was experienced within
the first 2 weeks of patient enrollment, with relative hazard increasing over time; this
suggests that guideline compliance is particularly important to the immediate health of a
patient with heart failure, no matter the severity of heart failure (as designated by NYHA
class). With the exception ofthe

IS-3~

(HR-IS to 30 day = I.S9, p=0.62) day period, a

decreased hazard rate was observed for each of the specified time periods. Observed risk
variances exhibited may be attributed to different phases of HF over the study period,
with individuals failing early at more severe stages ofHF than those at the later stages of
the study. In addition, multiple failures over the study period without having a HF-related
rehospitalization may contribute to the observed variances in risk.
Individuals in NYHA class IV were at an increased risk of rehospitalization
relative to those in class II and III, which is expected based on the criteria for
classification, but especially within the first 30 days of enrollment. Cumulative hazard
decreases ranged between 20-40% among those receiving appropriate treatment
therapies, suggest that appropriate treatment from the outset of hospitalization conferring
even a small increase in health outcomes would provide a dramatic benefit, given the
relative expense associated with a single heart failure hospitalization. The results of the
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analysis argue the importance of treatment adherence among heart failure patients, no
matter what stage of heart failure (but especially in the most severe stage and within the
first 30 days.
The original study, enrolling patients from medical institutions in multiple regions
of the United States, collected a random sample of individuals representative of the US
population. The main limitation of the analysis ofthis data is the small sample size
(n=128), resulting in lack of power to detect statistical significance. The limited sample
size reduced the ability to make a fully inclusive model integrating several demographic
characteristics; race and sex, which were tested in univariate analysis, were dropped from
later analyses due to a lack of effect. Comorbid conditions (i.e., hypertension, diabetes,
hypercholesterolemia, hyperlipidemia, obesity, and smoking status) which were recorded
at enrollment for each patient were excluded from regression models to limit the number
of variables used in the analyses. To account for the health implications of these
comorbidities and their effects on an individual's overall survival probability, regression
analysis proceeded under the assumption that patients with moderate to severe heart
failure were receiving appropriate interventions and counseling for lifestyle modification
for their accompanying health risks (such as diabetes, hypertension, obesity and
smoking)- which typically interact negatively with the heart.
In addition, the argument for appropriate treatment was simplified for the
purposes of analysis, using an all-or-none approach. In future studies, a stratification of
partial adherence to guidelines could be used to indicate any weaknesses in a specific
area of heart failure treatment, which extends beyond the scope of this research (ex.
Presence of hypokalemia and adverse interactions with spiranolactone). Of greater
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importance is the use of an intention-to-treat model in the original study, which assumes
a patient complies with the recommended treatments; a study assessing medication intake
at each rehospitalization event may provide a more accurate depiction of the hazard rates
in these heart failure patients, setting apart those that follow prescribed treatment with
those that do not.
Given the overall mortality rate among heart failure patients, the results from the
regression analysis should be assessed on the basis of their clinical implications,
considering the relative risks and survival effects among the patients enrolled. The small
sample size (n=128) did not achieve statistical significance for more complex models
including variables such as comorbid conditions, as stratification often lead to small
subcategories. Because of this, a simplified model was created to account for the lack of
power. The effect size (decreased hazard among those in which treatment guidelines were
adhered) solely due to treatment is a large estimate which should be considered of
clinically meaningful importance, due to an already increased risk of failure in the target
population. The confidence interval in the overall model, suggest a positive effect in this
patient population. Given that the study population was a representation of a diverse
group of heart failure patients, the effect size oftreatment can be extrapolated to the
larger population of heart failure patients. Effect size within the immediate time after
enrollment into the study suggests that compliance with the set ACC!AHA guidelines
from the outset of heart failure would improve immediate rehospitalization rates, which
has both a workload benefit as well as a monetary benefit to the medical institutions
receiving these patients. Additionally, since heart failure treatment is one of the largest
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expenditures in healthcare, even a small reduction in overall mortality would benefit our
healthcare system on a large scale.
DISCUSSION:
Previous studies looking at the relationship between treatment and
rehospitalization rates among heart failure patients have concluded similar results,
arguing that appropriate treatment reduces the rates in which a patient is readmitted; the
implication, although intuitive, is often understated based on the cumulative risk among
these patients. What makes this analysis unique is that importance of appropriate
treatment has been assessed not only on a larger time scale (1 year), but it has also
analyzed the effect at various smaller time frames: 0-14 days, 15-30 days, and 31-180
days. These time frames not only have a clinical importance, but an economic
importance. As stated previously, heart failure is one of the most expensive conditions in
terms of overall healthcare spending, accounting for approximately 2% of total costs
(estimated at 37 billion dollars). With the initiation of the Affordable Care Act (ACA),
hospitals and medical institutions will now incur penalties based on the percentage of
rehospitalizations assessed over these shorter time periods.
The Centers for Medicare and Medicaid Services (CMS's), in response to limited
improvement of 30 day rehospitalization rates between 2007 and 2010, implemented a
National Strategy for Quality Improvement in Health Care, the goal of this program
aiming to reduce hospitalizations by 20% at the end ofthis year. CMS' s estimated that
such a reduction would prevent 1.6 million hospitalizations and save an estimated $15
billion. The most important program in the effort to reduce rehospitalization is the
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Hospital Readmission Reduction Program (HHRP), specified in the bylaws of the ACA.
This program, which is expected to generate significant savings in the Congressional
Budget, is designed to align payment with outcomes, driving meaningful reductions in
all-cause readmissions. The measure proposed is a hospital-specific, risk-standardized 30
day readmission ratio which follows index admissions for acute myocardial infarction
(AMI) and HF. As a result, underperforming hospitals will incur a reduction of 1% or
less in Medicare reimbursements for inpatient services; payment penalties can increase to
2-3%, based on the higher readmission rates. This would translate into an average cost
per hospital of$125,000.4 Hospital readmission rates, based on 2010 data would have
placed half of all eligible hospitals at risk of penalties regardless of geography, bed size,
or teaching status.
The issue of proper treatment and penalty for readmission is one that has to be
weighed from the sides of the physicians and clinicians, and not that of the agencies
working to reduce rehospitalization rates. A couple of issues to contemplate with the
proposed hospital readmissions reduction program include higher readmissions rates
among hospitals serving low-income individuals, and hospitals keeping very ill patients
having higher readmissions/lower mortality. In addition, heart failure mortality may not
be the direct cause of readmission; any number of maladies or physical problems can
arise sending someone back to the hospital. The 20% reduction goal placed by CMS is
based on the average rate of rehospitalization among Medicare recipients within the first
month after hospital discharge for any purpose; however, readmission for only a limited
number of conditions (HF included) would be recorded when assessing penalties accrued.
From this study, it is clear that age, HF class, and especially treatment guideline
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adherence is an important determinant in the first 30 days; this is exhibited by an increase
in relative risk among age and NYHA class, and a decrease with treatment compliance
(listed previously in Table 2) as well as by the cumulative 30 day hazard reduction of
almost 35%. By the measures proposed, hospitals would benefit from focusing better
treatment on patients with heart conditions relative to all other conditions.
The guidelines for clinical practice set forth by the ACC/AHA are
recommendations based on the amount of clinical evidence backing certain therapies.
They are categorized by the amount of data on (level A-C) and effect size (class) of
treatment. While these guidelines are widely used and accepted by clinicians and
physicians, they are not all encompassing, as treatment for heart failure is complex. The
guidelines are set to be a baseline for treatment, however several clinical and biological
measures are often assessed upon patient examination which may modify the course of
medical action. From an epidemiological perspective, however, these levels of evidence
are something that could be translated into the evaluation of research outside of the
clinical realm. The possibility of having a standardized approach for research evaluation
in different areas of epidemiology, using reinforcement from multiple studies create an
"evidence-based" methodology could be beneficial in making recommendations in the
general public.
In conclusion, from this analysis we have assessed the economic and clinical
benefits of appropriate treatment for heart failure patients. Looking at various factors that
influence the overall rehospitalization rates including the severity of heart failure,
treatment compliance is arguably the most important variable within the results
generated. While the sample of patients was small in this study, the large effect -
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exemplified by hazard rates among those receiving appropriate treatment - argues the
clinical importance of adhering to the ACC/ AHA guidelines, while controlling for several
other factors that contribute to increased risk. Further studies with a larger sample size
would be needed to reaffirm the finding from this analysis with a strong statistical
significance. With the initiation of the Affordable Care Act, however, there is even more
of an incentive for hospitals to become thorough in their efforts to properly treat these
high risk patients, and the results from our study reaffirm this point.
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